MORRISTOWN, N.J., Feb. 6 /PRNewswire/ -- The Biotechnology Council of New Jersey (BCNJ) announced today that John W. Maki President and CEO of Vicus Therapeutics, LLC in Morristown, New Jersey has been elected to its Board of Trustees. The mission of the Board is to help foster a positive culture for biotechnology companies to prosper in New Jersey.
Vicus Therapeutics is a privately-held, clinical-stage biopharmaceutical company with a lead program in Phase II clinical trial for the treatment of cancer cachexia.
"New Jersey is a premiere location for biotechnology and pharmaceutical companies, and it is an honor to be recognized by an organization that is making such great strides in advancing the growth of the state's thriving life sciences industry," said John Maki.
John Maki has been President and CEO of Vicus Therapeutics since its formation in 2005. Previously, Mr. Maki was Managing Director of Technology Directors, Inc. and the Audax Group, a Principal of Bain Capital and a consultant at Bain & Company. Mr. Maki has over 20 years of industry experience and has been founding investor and/or Board Member of eleven life science companies. In addition, three of Mr. Maki's portfolio companies had successful IPOs and grew to a combined market capitalization exceeding $1.4 billion dollars. Mr. Maki is currently on the Board of Directors of 3DM, Addition Technology and Vicus Therapeutics. Mr. Maki received an AB in economics from Harvard University.
About Vicus Therapeutics
Vicus Therapeutics is a privately-held, clinical-stage biopharmaceutical company located in Morristown, NJ, developing novel strategic approaches to the treatment of cancer supportive care indications. Vicus's lead program, VT-122, is in Phase II clinical trial for the treatment of cancer cachexia in patients with advanced lung cancer. Additionally, Vicus has two preclinical programs for the treatment of oral mucositis and cancer fatigue. Vicus leverages its proprietary science to design and screen two-drug combinations that work together to reverse the body's maladaptive responses to cancer and its treatment. Vicus's development programs are powered by its network of leading clinical investigators in the US, India and Japan. This international network drives the high quality, rapid and cost effective clinical development of Vicus's product candidates.
Website: www.vicustherapeutics.com
About BCNJ
The Biotechnology Council of New Jersey was founded in 1994 by New Jersey biotechnology industry CEOs to serve as the voice of and advocate for the biotechnology industry in New Jersey. With more than 170 member companies, BCNJ is singularly focused on the growth and prosperity of New Jersey's rapidly expanding biotechnology cluster. For more information, visit the BCNJ Web site at www.biotechnj.org.
Vicus TherapeuticsCONTACT: John Maki, President and CEO, Vicus Therapeutics, LLC,+1-973-285-3175; or Tina Posterli, media, Rx Communications Group, LLC,+1-917-322-2565, tposterli@rxir.com
